S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Forecast, Price & News

$3.88
+0.29 (+8.08%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.60
$3.92
50-Day Range
$3.01
$3.96
52-Week Range
$2.95
$9.56
Volume
20,008 shs
Average Volume
16,755 shs
Market Capitalization
$31.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Lumos Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
355.3% Upside
$17.67 Price Target
Short Interest
Bearish
3.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Lumos Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$7,240 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.88) to ($2.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

406th out of 983 stocks

Pharmaceutical Preparations Industry

193rd out of 486 stocks


LUMO stock logo

About Lumos Pharma (NASDAQ:LUMO) Stock

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

Daniel Farb Buys 22% More Lumos Pharma Shares
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
"How war impacts the stock market"
Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your Retirement
8-K: LUMOS PHARMA, INC.
Lumos Pharma: Q1 Earnings Insights
Oppenheimer Remains a Buy on Soleno Therapeutics (SLNO)
See More Headlines

LUMO Price History

LUMO Company Calendar

Last Earnings
5/03/2023
Today
6/02/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUMO
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.67
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+363.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-31,060,000.00
Net Margins
-1,459.25%
Pretax Margin
-1,459.87%

Debt

Sales & Book Value

Annual Sales
$1.52 million
Book Value
$6.43 per share

Miscellaneous

Free Float
6,234,000
Market Cap
$31.13 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Richard J. Hawkins
    Chairman & Chief Executive Officer
  • John C. McKew
    President & Chief Scientific Officer
  • Robert J. Davis
    Vice President-Clinical Operations
  • Lori Lawley
    Chief Financial Officer
  • David B. Karpf
    Chief Medical Officer













LUMO Stock - Frequently Asked Questions

Should I buy or sell Lumos Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUMO shares.
View LUMO analyst ratings
or view top-rated stocks.

What is Lumos Pharma's stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Lumos Pharma's stock. Their LUMO share price forecasts range from $7.00 to $28.00. On average, they expect the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 363.7% from the stock's current price.
View analysts price targets for LUMO
or view top-rated stocks among Wall Street analysts.

How have LUMO shares performed in 2023?

Lumos Pharma's stock was trading at $3.61 at the start of the year. Since then, LUMO stock has increased by 5.5% and is now trading at $3.81.
View the best growth stocks for 2023 here
.

When is Lumos Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our LUMO earnings forecast
.

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) posted its earnings results on Wednesday, May, 3rd. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.23. The firm had revenue of $0.69 million for the quarter, compared to analysts' expectations of $0.31 million. Lumos Pharma had a negative trailing twelve-month return on equity of 48.26% and a negative net margin of 1,459.25%.

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and

What is Lumos Pharma's stock symbol?

Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO."

Who are Lumos Pharma's major shareholders?

Lumos Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.81%), Marquette Asset Management LLC (0.38%), Greenwich Wealth Management LLC (0.37%) and Private Advisor Group LLC (0.24%). Insiders that own company stock include James E Flynn, John C Mckew, Kevin M Lalande, Kevin M Lalande, Richard J Hawkins and Thomas A Raffin.
View institutional ownership trends
.

How do I buy shares of Lumos Pharma?

Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lumos Pharma's stock price today?

One share of LUMO stock can currently be purchased for approximately $3.81.

How much money does Lumos Pharma make?

Lumos Pharma (NASDAQ:LUMO) has a market capitalization of $31.13 million and generates $1.52 million in revenue each year. The company earns $-31,060,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis.

How can I contact Lumos Pharma?

Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The official website for the company is www.lumos-pharma.com. The company can be reached via phone at (512) 215-2630, via email at investor@linkp.com, or via fax at 515-296-3520.

This page (NASDAQ:LUMO) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -